Britain’s biotech firms now have a code of conduct designed to prevent them
from overhyping the progress of experimental drugs. Published this week by the
BioIndustry Association (BIA), the code was drafted in the wake of a damaging
scandal last year
(This Week, 4 July 1998, p 20).
From now on, companies must
have their scientific and clinical progress audited by external experts. Failure
to comply could mean expulsion from the BIA.
More from New ÒÁÈ˾þÃ
Explore the latest news, articles and features
Mind
The relationship recession is even bigger for Gen Z than we thought
News
Technology
Killer robots are here – we must finally decide whether to accept them
Leader
Technology
Quantum computer quickly mines cryptocurrency while using less energy
News
Mind
How to sparkle in conversation with strangers
Comment
Popular articles
Trending New ÒÁÈ˾þà articles
1
Fully autonomous drones have killed human soldiers for the first time
2
The relationship recession is even bigger for Gen Z than we thought
3
Quantum computer quickly mines cryptocurrency while using less energy
4
El Niño has started and the weather could get weird
5
How to sparkle in conversation with strangers
6
Toy universe shows that time could be a quantum illusion
7
First working nuclear clock heralds a new era in timekeeping
8
Vaping after quitting smoking is linked to lung cancer
9
Mercury may have gained all of its unexpected water in a single day
10
Mysterious ‘cold blob’ in the Atlantic suggests the AMOC is weakening
